A Double-Blind, Placebo-Controlled, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of JUV-161 Administered Subcutaneously to Healthy Adult Volunteers
Latest Information Update: 23 May 2025
At a glance
- Drugs JUV 161 (Primary)
- Indications Myotonic dystrophy
- Focus Adverse reactions; First in man
- Sponsors Juvena Therapeutics
Most Recent Events
- 19 May 2025 According to the Juvena Therapeutics Media Release, company announced that it is enrolling participants into this trial.
- 18 Apr 2025 Status changed from not yet recruiting to recruiting.
- 09 Apr 2025 Status changed from planning to not yet recruiting.